Neurocrine Biosciences, Inc. NBIX

US Biotechnology

$168.86 ▲ +2.57% (+$4.23)

Open $166.66

Prev Close $164.63

Day Range $162.99 – $169.89

52W Range $122.14 – $186.12

Market Cap $17.09B

P/E (TTM) 23.85

Beta 0.29

EPS (TTM) $6.74

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	1996-05-23
Shares Out.	101,650,000
Website	neurocrine.com/ ↗
Phone	18009279800
Employees	2,500
Revenue	$1.12B
Gross Profit	$1.10B
Net Income	$206.5M
Free Cash Flow	$1.04B
Total Assets	$5.63B
Total Liabilities	$1.75B
Equity	$3.88B

About Neurocrine Biosciences, Inc.

Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.

Neurocrine Biosciences, Inc. is a publicly traded company under the ticker symbol NBIX on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.